- ProQR appoints three new members to the Company’s
Scientific Advisory Board: Dr. Phil Zamore, Dr. Cy Steinand Dr. Scott Armstrong, who bring a tremendous amount of experience in the fields of RNA-based therapeutics and genetic pediatric diseases.
- The new members will join Dr.
Art Levinand Dr. Annemieke Aartsma-Ruson the Scientific Advisory Boardthat will play a strategic role in the development of the Company’s pipeline. The Scientific Advisory Boardwill also play a key role in the advancement of the Company’s novel and proprietary next generation RNA editing technology, Axiomer®, that utilizes endogenous RNA editing processes to target a number of genetic disorders.
“We are very pleased to have such a talented and experienced SAB. Science is at the core of everything we do at ProQR, and with this group as our key advisors we can be more successful in translating innovative science into therapies for patients in need,” said
The SAB now consists of five members, Dr.
Art Levin PhD, has more than two decades of experience in RNA drug development from discovery through drug registration, both in large pharma and biotech companies. He has been key to the development of numerous of oligonucleotides, including the first approved antisense medicines, and the first microRNA-targeted therapeutic in clinical trials. He is currently the Executive Vice President, Research and Development at Avidity Biosciences, Dr. Levin has published over 60 scientific articles and served as a director of the
“ProQR has been working on cutting-edge RNA technologies since its inception,” said
Phil Zamore PhD is a Howard Hughes Medical Institute Investigator, Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the
Cy Stein PhD, MD, is a Professor of Medical Oncology and Molecular and Cellular Biology and the former chair of the
Annemieke Aartsma-Rus PhD, professor of Translational Genetics at the
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding our SAB members, and statements regarding our ongoing and planned discovery and development of our pipeline and the advancement of our novel and proprietary technologies. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, manufacturing processes and facilities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors in our filings made with the
T: +1 858 245 3983
T: +31 6 2970 4513 (NL)
T: + 1 213 261 8891 (US)